DEF 14A: Champions Oncology Sets Date for Annual Stockholders Meeting, Outlines Key Proposals

Champions Oncology will hold its annual stockholders meeting on October 14, 2024, to elect directors, ratify the appointment of its accounting firm, and vote on executive compensation.

Summary

• Champions Oncology will hold its Annual Meeting of Stockholders on October 14, 2024, at its headquarters in Hackensack, New Jersey.
• Stockholders will vote on the election of seven directors, ratification of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending April 30, 2025, and a non-binding advisory resolution on executive compensation.
• The record date for determining stockholders eligible to vote is August 26, 2024.
• The Board of Directors recommends voting FOR all director nominees, FOR the ratification of EisnerAmper LLP, and FOR the advisory resolution on executive compensation.
• Proxy materials are available online, and stockholders can vote electronically or by mail.
• As of the record date, there were 13,593,766 shares of common stock outstanding.
• The Board of Directors has determined that Messrs. Ackerman, Sidransky, Mendelson, Tobin, Breitfeld and Brainin are independent as defined in Rule 5605(a)(2) of the Nasdaq Stock Market Rules (Nasdaq Rules).

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The company is following standard corporate governance practices.

Positives

• The company is providing electronic access to proxy materials to reduce costs.
• The Board of Directors is actively engaged in risk oversight.
• The company has a Code of Business Conduct and Ethics in place.
• The company has a compensation recovery and clawback policy.

Negatives

• Mr. Brainin's Form 4 with respect to option grants were filed late.
• The company reported net losses for 2023 and 2024.

Risks

• The proxy statement mentions cybersecurity risks, although no material impact has been identified to date.
• The company's success depends on retaining key personnel, including executive officers and directors.
• The advisory vote on executive compensation is non-binding, so the Board is not obligated to follow the stockholders' recommendation.

Future Outlook

The Board of Directors is not aware of any other matter which may be presented for action at the 2024 Annual Meeting of Stockholders, but should any other matter requiring a vote of the stockholders arise at the 2024 Annual Meeting, it is intended that the proxies will be voted with respect thereto in accordance with the best judgment of the person or persons voting the proxies, discretionary authority to do so being included in the proxy.

Management Comments

• The Board of Directors recommends that stockholders vote FOR all of the proposed nominees for director, FOR the ratification of the appointment of EisnerAmper LLP, and FOR the non-binding resolution approving the compensation of our named executive officers.

Industry Context

This proxy statement is a standard document for publicly traded companies, outlining the matters to be voted on at the annual meeting and providing information about the company's directors, executive compensation, and corporate governance practices.

Comparison to Industry Standards

• The director independence standards align with Nasdaq requirements.
• The executive compensation discussion and tables follow SEC guidelines.
• The audit fee disclosure is typical for publicly traded companies.
• The company's clawback policy is in line with recent SEC rules.

Related Party Transactions

• Dr. Sidransky, a director, received $36,000 in consulting fees from the company during the fiscal years ended April 30, 2024 and 2023.

Stakeholder Impact

• Stockholders have the opportunity to vote on key matters affecting the company.
• The election of directors will shape the company's leadership and strategic direction.
• The advisory vote on executive compensation allows stockholders to express their views on pay practices.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold the Annual Meeting of Stockholders on October 14, 2024.
• The company will file a Current Report on Form 8-K with the SEC to announce the final voting results within four business days of the Meeting.

Key Dates

Keywords

proxy statement, annual meeting, stockholders, directors, executive compensation, EisnerAmper, audit committee, corporate governance, Champions Oncology